Danaher Corporation

NYSE:DHR Stock Report

Market Cap: US$166.9b

Danaher Valuation

Is DHR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DHR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DHR ($229.65) is trading above our estimate of fair value ($204.29)

Significantly Below Fair Value: DHR is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DHR?

Key metric: As DHR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DHR. This is calculated by dividing DHR's market cap by their current earnings.
What is DHR's PE Ratio?
PE Ratio42.2x
EarningsUS$3.93b
Market CapUS$166.92b

Price to Earnings Ratio vs Peers

How does DHR's PE Ratio compare to its peers?

The above table shows the PE ratio for DHR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30x
TMO Thermo Fisher Scientific
32.3x11.5%US$201.2b
A Agilent Technologies
29.8x8.1%US$38.7b
IQV IQVIA Holdings
25.5x13.5%US$36.2b
MTD Mettler-Toledo International
32.4x7.4%US$26.0b
DHR Danaher
42.2x13.4%US$166.9b

Price-To-Earnings vs Peers: DHR is expensive based on its Price-To-Earnings Ratio (42.2x) compared to the peer average (30x).

Price to Earnings Ratio vs Industry

How does DHR's PE Ratio compare vs other companies in the US Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
REPC.F RepliCel Life Sciences
0.07xn/aUS$65.00k
No more companies available in this PE range
DHR 42.2xIndustry Avg. 36.9xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DHR is expensive based on its Price-To-Earnings Ratio (42.2x) compared to the Global Life Sciences industry average (36.9x).

Price to Earnings Ratio vs Fair Ratio

What is DHR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DHR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42.2x
Fair PE Ratio35.5x

Price-To-Earnings vs Fair Ratio: DHR is expensive based on its Price-To-Earnings Ratio (42.2x) compared to the estimated Fair Price-To-Earnings Ratio (35.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DHR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$229.65
US$287.70
+25.3%
5.8%US$315.00US$255.00n/a26
Dec ’25US$239.69
US$290.13
+21.0%
5.7%US$315.00US$255.00n/a24
Nov ’25US$247.76
US$289.75
+16.9%
5.9%US$315.00US$255.00n/a24
Oct ’25US$274.56
US$289.35
+5.4%
7.1%US$333.00US$250.00n/a23
Sep ’25US$269.31
US$285.87
+6.1%
6.4%US$310.00US$250.00n/a22
Aug ’25US$280.76
US$286.15
+1.9%
6.5%US$310.00US$250.00n/a21
Jul ’25US$244.51
US$273.39
+11.8%
7.6%US$300.00US$220.00n/a23
Jun ’25US$256.80
US$272.78
+6.2%
7.5%US$300.00US$220.00n/a23
May ’25US$246.89
US$270.08
+9.4%
8.8%US$300.00US$208.00n/a24
Apr ’25US$247.79
US$262.17
+5.8%
9.1%US$300.00US$208.00n/a24
Mar ’25US$255.87
US$260.75
+1.9%
9.3%US$300.00US$208.00n/a24
Feb ’25US$245.13
US$260.33
+6.2%
9.3%US$300.00US$208.00n/a24
Jan ’25US$231.34
US$247.16
+6.8%
10.3%US$306.00US$205.00n/a25
Dec ’24US$223.48
US$241.52
+8.1%
10.3%US$306.00US$208.00US$239.6923
Nov ’24US$190.00
US$242.39
+27.6%
10.6%US$306.00US$208.00US$247.7623
Oct ’24US$248.10
US$283.58
+14.3%
5.4%US$306.00US$240.00US$274.5623
Sep ’24US$265.59
US$283.97
+6.9%
6.2%US$325.00US$240.00US$269.3124
Aug ’24US$255.00
US$285.04
+11.8%
6.8%US$328.00US$240.00US$280.7622
Jul ’24US$240.00
US$278.59
+16.1%
9.0%US$356.00US$250.00US$244.5122
Jun ’24US$232.69
US$279.50
+20.1%
8.8%US$356.00US$250.00US$256.8022
May ’24US$241.73
US$282.86
+17.0%
9.7%US$356.00US$242.00US$246.8921
Apr ’24US$252.04
US$302.35
+20.0%
8.2%US$365.00US$242.00US$247.7920
Mar ’24US$245.36
US$302.85
+23.4%
8.2%US$365.00US$242.00US$255.8720
Feb ’24US$267.50
US$302.85
+13.2%
8.2%US$365.00US$242.00US$245.1320
Jan ’24US$265.42
US$304.71
+14.8%
8.0%US$342.00US$242.00US$231.3421
Dec ’23US$274.54
US$305.63
+11.3%
8.2%US$342.00US$242.00US$223.4819

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 22:55
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/27
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Danaher Corporation is covered by 54 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Catherine Ramsey SchulteBaird
Robert CornellBarclays